AstraZeneca picks up suite of new Covid-19 antibodies, shining spotlight on Oxford-tied startup

AstraZeneca is taking another stab at developing antibodies for Covid-19.

Having partnered with Vanderbilt University researchers to develop the long-acting antibody combo now known as Evusheld, AstraZeneca this time is betting on newly-launched RQ Biotechnology, a UK-based outfit with roots at the University of Oxford and medical research charity LifeArc.